Biosimilar Development solution center

1. Doubling Up For Speed In Biomanufacturing 12/12/2025

   Accelerate drug development and reduce risk with parallel operations. Learn how leveraging CDMO partnerships while building internal capabilities can cut costs and speed your path to market.

2. CDMO Or No CDMO... That Is The Question 12/12/2025

   Success depends on assessing internal capabilities and knowing when outsourcing can accelerate timelines. Learn how strategic decisions reduce risk, avoid costly delays, and keep your organization competitive.

3. CDMOs - Key Collaborators In Streamlining Drug Development 12/12/2025

   Accelerating biologics development requires more than speed. Discover how the right CDMO partnership can streamline processes and help you reach the market faster without sacrificing control.

4. Scaling Up Bioprocesses Through A CDMO 12/12/2025

   Scaling biopharma processes is complex. Learn how flexibility, single-use systems, and strategic partnerships are helping manufacturers overcome these challenges and accelerate time to market.

5. 5 Reasons For Outsourcing Chromatography Resin Lifetime Studies 12/12/2025

   Outsourcing resin lifetime studies accelerates timelines, reduces costs, and minimizes risk. Gain expert support, free up resources, and optimize resin performance without tying up your team or equipment.

6. Is Your Biologics CDMO Transparent? 12/12/2025

   Transparency and collaboration with a CDMO are vital for reducing risk and protecting IP. Discover four essential practices, from clear communication to IP safeguards, that help build trust.

7. How To Double Up With A CDMO To Reduce Risk 12/12/2025

   Parallel operations with a CDMO can reduce risk and accelerate timelines by enabling simultaneous process development and manufacturing. Learn how this approach supports facility design.

8. Biologics CDMO: 3 Qualities Often Overlooked 12/12/2025

   A partnership can deliver more than process support. Transparency, regulatory expertise, and IP protection are critical benefits that safeguard your autonomy and innovation while enabling global success.

9. Product Carbon Footprints: The Next Frontier In Sustainable Innovation 12/12/2025

   Product Carbon Footprints reveal true lifecycle emissions, enabling collaboration, innovation, and informed decisions. Learn why moving from estimates to evidence is essential for reducing Scope 3 impact.

10. FDA Draft Guidance On CES Signals More Reliance On Toxicity And PK 11/19/2025

    The technology to measure alternative metrics is vastly improved. Now, FDA joins other regulators in deprioritizing comparative efficacy studies for biosimilars.